Kerry Fisher

Kerry Fisher has a diverse work experience. In 2001, Kerry served as the CEO of Hybrid Systems Ltd until 2009. In 2005, Kerry became a University Lecturer at the University of Oxford. In 2010, Kerry took on the role of Director at The Native Antigen Company until 2020. In the same year, Kerry founded and became a Scientific Advisor at PsiOxus Therapeutics Ltd. Kerry later became the Founder and Scientific Advisor at PsiOxus Therapeutics from 2012 onwards. Most recently, in 2018, Kerry co-founded Theolytics.

Kerry Fisher pursued their education starting from 1993 to 1997 at the University of Aberdeen, where they obtained a Bachelor of Science (Honors) degree in Biotechnology. Kerry'sfield of study included Microbiology, Immunology, Biochemistry, and Virology. Following this, from 1997 to 2001, they attended the University of Birmingham, undertaking a Doctor of Philosophy (PhD) degree in Therapeutic gene delivery through an Astrazeneca CASE studentship.